An ambulatory surgery center typically sells for 6x–12x EBITDA, making ASCs among the most premium-valued healthcare assets in the M&A market. The U.S. ASC industry includes approximately 6,100 Medicare-certified surgery centers performing over 28 million procedures annually, generating an estimated $45 billion in total revenue. ASCs have become one of the most actively acquired healthcare asset classes, driven by the shift of procedures from hospital inpatient and outpatient settings to lower-cost ambulatory facilities — a trend accelerated by CMS policy expanding the list of procedures approved for ASC settings and by commercial payer preference for lower-cost sites of service.

The primary valuation method for ASCs is EBITDA — earnings before interest, taxes, depreciation, and amortization. EBITDA is the standard because most ASCs are large enough to attract institutional buyers who evaluate facilities on their cash flow generation capability. ASC EBITDA multiples typically range from 6x to 12x, with the range driven by case volume per OR, specialty mix, surgeon diversification, payer contract quality, and geographic market dynamics. A center at 6x EBITDA typically has underutilized operating rooms, heavy surgeon concentration risk, lower-reimbursement specialty mix, and limited commercial payer contracts. A center at 12x runs at high utilization with diversified surgeons across premium specialties, strong commercial rates, and strategic geographic positioning in a growing market.

For smaller ASCs where the physician-owner functions as both surgeon and administrator, Seller's Discretionary Earnings provides an alternative calculation. SDE adds back the owner-surgeon's total compensation, benefits, and personal expenses to net income. The complication in ASC SDE calculation is that the owner-surgeon's clinical production directly generates revenue — if they perform 800 cases per year at $2,000 average net revenue, their departure removes $1.6M in revenue alongside their compensation. Buyers evaluate how much revenue is owner-surgeon-dependent versus generated by independent surgeons on the panel.

Revenue multiples for ASCs typically fall between 1.0x and 2.5x, reflecting the relatively strong margin profile of ambulatory surgery. Well-operated ASCs generate EBITDA margins of 25–40%, making them among the most capital-efficient healthcare businesses. Revenue multiples should be evaluated alongside payer mix — commercial revenue at 200–300% of Medicare rates produces dramatically different economics than a Medicare-heavy facility, even at identical case volumes.

The unique valuation factor that distinguishes ASC transactions from all other healthcare M&A is the surgeon-as-revenue-source dynamic. In every other business, the company generates revenue through its own operations, employees, or brand. In an ASC, revenue is generated by independent surgeons who choose to bring their cases to your facility — and who can redirect those cases to any competing facility or hospital outpatient department at any time. This means the ASC's revenue base is essentially a collection of surgeon relationships, not a stable company asset. The facilities that command premium multiples have mitigated this risk through three mechanisms: surgeon diversification (no surgeon above 15–20% of volume), structural commitment devices (equity ownership, governance participation, long-term operating agreements), and competitive positioning that makes the facility the surgeon's preferred venue (efficient scheduling, quality nursing staff, modern equipment). When a buyer evaluates an ASC, they are essentially asking: will these surgeons continue bringing cases here after the ownership changes? The answer determines the multiple. Centers where surgeons have equity, governance roles, and documented case volume commitments over many years present low transition risk. Centers where a few non-equity surgeons could redirect cases to a hospital outpatient department present high risk and receive discounted multiples. For ASC owners preparing to sell, building surgeon diversification and commitment is the single most impactful pre-sale investment.

The ASC M&A market is highly active with well-capitalized institutional buyers. National ASC management companies (USPI/Tenet, AmSurg/Envision, SCA Health) operate hundreds of centers and acquire continuously. PE-backed surgical platforms build portfolios across specialties and geographies. Hospital systems acquire ASCs to recapture outpatient surgical volume and align with surgeon partners. Health plans acquire or partner with ASCs to control surgical costs. For centers with strong case volume, diversified surgeon panels, premium payer contracts, and modern facilities, the market offers competitive multiples and multiple bidding parties. Centers with surgeon concentration, underutilized ORs, or aging facilities should invest in diversification and facility improvements before pursuing a sale.

Use our free calculator above to get your instant estimate, then track your value monthly with YourExitValue.